A trial looking at dalotuzumab and ridaforolimus for children and young people with advanced cancer (MK-8669-062)
Cancer type:
Status:
Phase:
This trial looked at dalotuzumab alone and in combination with ridaforolimus. It was for children and young people whose cancer had continued to grow despite other treatment.
The trial was open for people to join between 2012 and 2013. The team published results in 2016. There is a link to more information in the ‘Summary of results’ section below.
More about this trial
Dalotuzumab (MK-0646) is a type of immunotherapy called a monoclonal antibody. It recognises cancer cells by looking for a specific protein on them.
Ridaforolimus (MK-8669) is a type of targeted cancer treatment called a cancer growth blocker. It stops the signals that cancer cells use to divide and grow.
This trial was for children and young people up to 17 years old. They had a number of different cancers, including cancer of the:
- bone or soft tissue (Ewing’s sarcoma)
- muscle cells (rhabdomyosarcoma)
- adrenal gland (adrenal cortical cancer)
- nerve cells (neuroblastoma)
The trial had 3 parts.
Part 1 looked at dalotuzumab alone. People in this part had different doses of dalotuzumab. This was so the team could find the best dose to use.
Parts 2 and 3 were due to look at the combination of dalotuzumab and ridaforolimus. But they were not completed.
The main aims of this trial were to find out:
- the best dose of dalotuzumab and ridaforolimus to use
- what happens to these drugs in the body
- more about the side effects
Summary of results
We aim to add a lay summary of results to all the trials on our database. Unfortunately we have not been able to include a summary for this one.
There is more information about the results in the link below.
Phase 1 study of dalotuzumab monotherapy and ridaforolimus - dalotuzumab combination therapy in paediatric patients with advanced solid tumours
Didier Frappaz and others
European Journal of Cancer, 2016. Volume 62, pages 9-17.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Andrew Pearson
Supported by
Experimental Cancer Medicine Centre (ECMC)
Merck, Sharp & Dohme
NIHR Clinical Research Network: Cancer
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
